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Introduction
Asthma is one of the leading causes of morbidity 
worldwide, with up to 18% of the population 
affected [GINA, 2016]. The economic burden of 
asthma is tremendous, at €19 billion in Europe 
alone [Dominguez-Ortega et al. 2015]. According 
to common guidelines, the initial treatment of 
asthma consists of inhaled corticosteroids (ICS) 
with the option of increasing the dose or to add 
on a long-acting beta agonist (LABA) in case of 
a persistent lack of asthma control. However, 
up to 40% of asthma patients remain sympto-
matic despite undergoing treatment modification, 
which suggests a need for additional treatment 
alternatives beside leukotriene modifiers (LTRA), 
systemic corticosteroids, anti-immunoglobulin 
(Ig)E or methylxanthines [Rabe et al. 2004].
Short-acting anticholinergic substances such as 
ipratropium bromide in add-on therapy with 
β2-agonists and ICSs have demonstrated a dose-
dependent effect on hospital admission rates and 
pulmonary function parameters, both in children 
and adults [Rodrigo and Castro-Rodriguez, 
2005]. Due to their lesser bronchodilatory 
potency and their short duration of action, their 
main therapeutic benefit may remain in managing 
an acute asthma exacerbation [Rodrigo and 
Rodrigo, 2002]. However, the release of acetyl-
choline has an influence on both bronchial tone 
and airway inflammation. Acetylcholine leads to 
contraction and proliferation of airway smooth 
muscles, mucus secretion, vasodilation and 
release of pro-inflammatory mediators by airway 
epithelial cells [Quizon et al. 2012]. Pretreatment 
with tiotropium results in prevention of allergen-
induced airways smooth muscle thickening, 
mucous gland hypertrophy, interleukin (IL)-13-
induced goblet cell metaplasia and eosinophilic 
inflammation in animal models [Kistemaker and 
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Gosens, 2015]. This effect seems to be mediated 
primarily by blocking the type 3 muscarinic recep-
tor (M3) (Table 1). While acknowledging these 
contributions to the pathophysiology of asthma, a 
long-acting anticholinergic agent might provide a 
more sustained therapeutic effect compared with 
the short-acting anticholinergic substances, and 
might therefore represent an alternative control-
ler as an add-on to ICSs.
Actually, three long-acting anticholinergic sub-
stances are approved for the treatment of COPD: 
glycopyrrolate, umeclidinium and tiotropium. 
Glycopyrrolate prolonged bronchodilation and 
bronchoprotection compared with ipratropium 
and placebo in a proof-of-concept study [Hansel 
et al. 2005], but further studies are only in prepa-
ration. A recently published dose–effect study of 
umeclidinium in asthmatic patients not treated by 
ICS did not support a therapeutic benefit [Lee 
et al. 2015a]. However, another study investigat-
ing the effect of add-on umeclidinium to ICS 
versus ICS + LABA or ICS alone demonstrated 
an improvement of trough forced expiratory vol-
ume in 1 second (FEV1) and morning and even-
ing peak expiratory flow (PEF) compared with 
ICS alone [Lee et al. 2015b]. Patients with fixed 
bronchial obstruction showed the greatest bene-
fit. Tiotropium has been approved for the indica-
tion of chronic obstructive pulmonary disease for 
more than 10 years. With a maximum effect after 
30–60 minutes, cholinergic transmission is 
blocked for around 35 hours, which enables a 
once-daily admission. Although tiotropium also 
binds to M1 and M2 receptors, it dissociates 
more slowly from the M3 receptor. Within recent 
years, a systematic study program on the thera-
peutic effects of tiotropium with respect to the 
indication of asthma was added to preliminary 
studies. As a result of these studies, tiotropium 
bromide has recently been included into the 
revised Global Initiative for Asthma (GINA) 
2015 strategy as an alternative add-on therapy, at 
steps 4 and 5, in adult patients with a history of 
exacerbations [GINA, 2016], and the label of tio-
tropium has been extended to include asthma by 
governing drug organizations. This article sum-
marizes the major results of tiotropium in the 
treatment of asthma in adult patients.
Proof-of-concept studies
A first, preliminary, double-blind, placebo-con-
trolled study investigated the duration of protec-
tion of three different single doses of tiotropium 
(10, 40, and 80 μg), inhaled with a dry powder 
inhaler, against methacholine-induced broncho-
constriction in 12 male asthmatic patients 
[O’Connor et  al. 1996]. The main result was 
that the authors could demonstrate a significant 
dose-dependent protection against methacho-
line challenge lasting for 48 hours, and a mild 
bronchodilating effect for up to 25 hours.
A further placebo-controlled methacholine prov-
ocation study in 10 asthmatic patients confirmed 
the effect of a single inhalation of tiotropium. A 
dose of 18 μg of tiotropium inhaled with the 
Spiriva HandiHaler resulted in significant protec-
tion, even with a maximum methacholine dose of 
1600 μg and only 30 minutes after administration 
[Terzano et  al. 2004]. Although the number of 
patients was low in both preliminary studies, the 
results are important, because they demonstrated 
significant and sustained protection against meth-
acholine challenge with once daily inhalation of 
tiotropium and an early onset of action. Compared 
with a pretreatment dose of 40 μg ipratropium, 
18 μg of tiotropium led to a significantly higher 
bronchoprotective effect after standardized metha-
choline provocation in 44 patients with intermit-
tent asthma 60 minutes after the time of inhalation; 
the effect of tiotropium was comparable with oxi-
tropium in this study [Sposato et al. 2008].
Table 1. Effects of acetylcholine in the pathophysiology of asthma mediated by type 3 muscarinic receptors 
(modified from [Kistemaker and Gosens, 2015]).
Asthma relevant changes Cells
Smooth muscle cell thickening Smooth muscle cell
Mucus secretion Epithelial cell, submucosal gland
Proliferation of fibroblasts Fibroblast
Extracellular matrix production Fibroblast
Th2 cytokine release Macrophage, lymphocyte, neutrophil
Airway remodeling Smooth muscle cell
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Again, 18 μg of tiotropium, added once daily to 
salmeterol and fluticasone in 25 severely asth-
matic patients, provided significant improve-
ment of lung function after reducing the ICS to 
half of the dose for 4 weeks. However, no influ-
ence on quality of life or symptoms could be 
demonstrated [Fardon et al. 2006]. Nevertheless, 
this preliminary study was important, because it 
demonstrated for the first time the potential of a 
combined add-on therapy of salmeterol and tio-
tropium to improve lung function despite a ster-
oid-sparing treatment adjustment in severe 
asthmatic patients.
A few of these early proof-of-concept studies 
focussed on subgroups of severely asthmatic 
patients, who might benefit most from tiotropium 
inhalation. A Japanese study with a limited num-
ber of 17 asthmatic patients on high-dose ICS 
showed significant improvement of FEV1 after 4 
weeks of treatment. Those patients with predomi-
nantly neutrophilic-induced sputum responded 
better compared with those with a higher sputum 
eosinophilic level [Iwamoto et  al. 2008]. Major 
limitations of this study were the small number of 
patients and the lack of a placebo arm. About 
33% of 138 severely asthmatic patients from 
Korea, who inhaled 18 μg of tiotropium once 
daily for 12 weeks in addition to a high-dose ICS 
plus LABA, responded to the therapy (with an 
improvement of FEV1 ⩾ 15% or ⩾200 ml for ⩾8 
weeks). Significantly, the presence of Arg16Gly 
polymorphism in ADRB2 was associated with a 
response to tiotropium [Park et al. 2009]. Again, 
as a consequence of the small sample size and 
the lack of a placebo arm, the effect of other 
confounding factors on the results, especially the 
ethnicity of the patients, is difficult to estimate.
Tiotropium add-on to ICS placebo-controlled 
studies
The Tiotropium Bromide as an Alternative to 
Increased Inhaled Glucocorticoid in Patients 
Inadequately Controlled on a Lower Dose of 
Inhaled Corticosteroid (TALC) study was the 
first larger and sufficiently powered study to test 
the add-on treatment effect of tiotropium in 
inadequately controlled asthmatic patients 
[Peters et al. 2010] (Table 2 displays the major 
results of all placebo-controlled and published 
trials). In this three-way, double-blind, triple-
dummy crossover trial, 210 adult asthmatics (age 
42.2 ± 12.3 yrs.) with uncontrolled asthma, who 
were uncontrolled despite having 160 μg of 
beclomethasone administered daily, were 
included, and 174 finished the trial. Patients 
were eligible to proceed with the trial if, after the 
4-week run-in period, the FEV1 was 70% or less 
of the predicted value; or if, during the last two 
weeks of the run-in period, they had symptoms 
on ⩾6 days/week, or needed rescue inhalation on 
⩾6 days/week, or on ⩾2 nights/week with awak-
ening due to asthmatic symptoms. Every patient 
completed three treatment periods, each for 14 
weeks, followed by wash-out periods of 2 weeks 
in between. The add-on therapy with 18 μg of 
tiotropium, added to the ICS, was compared 
with doubling the dose of ICS and the add-on of 
50 μg of salmeterol twice daily to the ICS. Add-on 
inhalation with tiotropium resulted in a higher 
increase in the morning PEF as the primary out-
come parameter compared with doubling the 
dose of ICS (mean difference of 25.8 l/min, p < 
0.001). Furthermore, tiotropium add-on therapy 
resulted in superiority in most secondary out-
come parameters (evening PEF, mean difference 
of 35.3 l/min, p < 0.001; proportion of asthma 
control days, mean difference of 0.079, p = 0.01; 
FEV1 before bronchodilation, mean difference of 
0.10 l, p = 0.004; daily symptom scores, mean 
difference of −0.11 points, p < 0.001) compared 
with doubling the dose of ICS, and was non-infe-
rior to add-on salmeterol. An analysis of the indi-
vidual and differential responses of the asthmatic 
patients to salmeterol and tiotropium showed 
that an acute response, especially to albuterol, 
predicted a positive response to tiotropium for 
the improvement of FEV1 and PEF [odds ratio 
(OR) 4.08, p < 0.001 and 2.12, p = 0.021, 
respectively] [Peters et  al. 2013]. A decreased 
FEV1/forced vital capacity (FVC) ratio and a 
higher cholinergic tone were further predictors of 
the clinical response to tiotropium, while other 
parameters such as sex, ethnicity, IgE level, spu-
tum eosinophil count, fraction of exhaled nitric 
oxide, asthma duration, and body mass index 
showed no influence. The studies might be criti-
cized because of the choice of PEF as the primary 
outcome parameter for asthma control, the rela-
tively short treatment periods and therefore, the 
lack of long-term safety data. However, the two 
major findings, the superiority of add-on tiotro-
pium compared with doubling the dose of ICS, 
and the non-inferiority to salmeterol are relevant 
for the grading of tiotropium within the different 
treatment options for asthma.
The asthma studies that followed after the TALC 
study were all performed with the Respimat 
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Table 2. Summary of placebo-controlled tiotropium studies in asthmatic patients.
Study Design Asthma 
severity
Standard therapy ICS 
(µg) LABA
Tiotropium 
(µg)
Duration 
(week)
Randomized 
patients
Primary 
outcome 
parameter
Intervention Results Safety
[Fardon 
et al. 2006]
R, DB, 
PC, CO
Severe 2 × 125 FP 
BD
25 SM 
BD
18 od 4 18 N/A FP 500 µg + SM versus FP 
500 µg + SM + TIO
Improvement of FEV1, PEF, 
FVC, no change in symptoms 
or QOL
N/A
[Peters 
et al. 2010]
R, DB, 
PC, CO
Moderate 2 × 40 or 2 × 
80 BM BD
50 BD 18 od 14 210 Morning PEF BM 160 µg + TIO versus 
BM 160 µg + SM versus BM 
320 µg
TIO superior to double dose 
BM, non-inferior to SM
AE/SAEs balanced 
across groups
[Kerstjens 
et al. 2011]
R, DB, 
PC, CO
Severe ⩾800 BU or 
equiv.
yes 10 versus 
5 od
8 107 Peak FEV1 ⩾800 µg BU + TIO 5 µg 
versus ⩾800 µg BU + TIO 
10 µg versus ⩾800 µg BU
TIO both doses superior to PL AE/SAEs balanced 
across groups
[Bateman 
et al. 2011]
R, DB, 
PC, PG
Moderate 400–1000 BU 
or equiv.
no 5 od 16 388 Morning PEF ICS + TIO versus ICS + SM 
25 bid versus ICS
TIO superior to PL and non-
inferior to SM
AEs balanced across 
groups, most SAEs in 
SM group
[Kerstjens 
et al. 2012]
R, DB, 
PC, PG
Severe ⩾800 BU or 
equiv.
yes 5 od 48 912 peak and 
trough FEV1
ICS + TIO versus ICS TIO superior to PL, reduction of 
severe exacerbation, delayed 
first severe exacerbation
AE/SAEs balanced 
across groups
[Beeh et al. 
2014]
R, DB, 
PC, CO
Moderate 400–800 BU 
or equiv.
no 5 versus 2.5 
versus 1.25 
od
4 149 Peak FEV1 ICS versus ICS + TIO all TIO dosages superior to PL, 
5 µg most superior
AE/SAEs balanced 
across groups
[Ohta et al. 
2015]
R, DB, 
PC, PG
Moderate 400–800 BU 
or equiv.
yes 5 versus 
2.5 od
52 285 Long-term 
safety
ICS versus ICS + TIO 5 µg 
versus ICS + TIO 2.5 µg
AE/SAEs balanced across 
groups, most of them mild-
moderate; peak FEV1 superior 
to PL in TIO 5 µg
AE/SAEs balanced 
across groups
[Timmer 
et al. 2015]
R, DB, 
PC, CO
Moderate 400–800 BU 
or equiv.
no 5 od versus 
2.5 bid
4 94 FEV1 AUC 
from 0-24h
ICS versus ICS + TIO 5 µg 
versus ICS + TIO 2.5 µg bid
both TIO dosages superior to 
PL, no difference between both 
TIO dosages
AE/SAEs balanced 
across groups
[Kerstjens 
et al. 2015]
R, DB, 
PC, PG
Moderate 400–800 BU 
or equiv.
no 5 versus 
2.5 od
24 2103 Peak and 
trough FEV1
ICS versus ICS + TIO 5 µg 
versus ICS + TIO 2.5 µg 
versus ICS + SM 50 µg bid
both TIO dosages and SM 
superior to PL, no difference 
between the treatment groups,
AE/SAEs balanced 
across groups
AE, adverse event; AUC, area under the curve; bid, twice daily; BM, beclomethasone; BU, budesonide; CO, crossover; DB, double blind; FEV1, forced expiratory volume in 1 second; FP, fluticasone propionate;  
FVC, forced vital capacity; ICS, inhaled corticosteroids; LABA, long-acting beta agonist; N/A, not applicable; od, once daily; PC, placebo controlled; PEF, peak expiratory flow; PG, parallel group; PL, placebo;  
QOL, quality of life; R, randomized; SAE, serious adverse event; SM, salmeterol; TIO, tiotropium.
C Vogelberg
http://tar.sagepub.com 529
Inhaler, which is characterized by the drug being 
released as a soft mist.
A total of 107 patients with uncontrolled, severe 
asthma were randomized in a double-blind, 
crossover study with three 8-week treatment 
periods, with either a tiotropium 5 μg, 10 μg, or 
placebo once daily add-on to a high-dose ICS 
plus LABA [Kerstjens et  al. 2011]. The peak 
FEV1 as the primary endpoint was significantly 
higher with both 5 and 10 μg of tiotropium com-
pared with the placebo (a difference of 139 ml 
and 170 ml, respectively, p < 0.0001). The 
trough FEV1 at the end of each treatment period 
was significantly higher in both dosage groups of 
tiotropium compared with the placebo group (86 
ml and 113 ml, respectively, p < 0.0004), as were 
the average morning and evening PEFs of the 
second half of each treatment period. There were 
no significant changes in asthmatic symptoms or 
quality of life. Subgroup analysis did not reveal 
any significant association between treatment 
effects and sex, FEV1 or reversibility at screen-
ing, smoking status, or asthma duration. The 
incidence of adverse events in the tiotropium and 
placebo groups was similar, with only dry mouth 
occurring more often in the 10 μg group. The 
study of Kerstjens and colleagues was the first of 
a series of further studies that used peak FEV1 
within three hours after dosing as outcome 
parameter [Kerstjens et al. 2011]. The differ-
ences of peak and trough FEV1 were not only sig-
nificantly higher in the tiotropium treated 
patients compared with placebo, but also clini-
cally relevant. The lack of a wash-out period 
between the different treatments and the short 
treatment periods might on the other hand have 
limited changes in patient reported outcomes.
In a comparative study of uncontrolled asthmatic 
patients with the B16-Arg/Arg genotype, who are 
supposed to respond less to β2-agonists, 388 
patients were randomized to a 16 week treatment 
with either 5 μg of tiotropium daily, 50 μg of sal-
meterol twice daily, or placebo; each as an add-on 
to 400–1000 μg of budesonide or its equivalent 
[Batemen et  al. 2011]. Changes in the weekly 
PEF from the last week of the run-in to the last 
week of treatment were significantly greater for 
tiotropium and salmeterol compared with the pla-
cebo (p < 0.05). Again, tiotropium was non-infe-
rior to salmeterol. The incidence of adverse events 
was similar in all groups, with only nasopharyngi-
tis occurring more frequently in the placebo 
group. Although the concerns about the use of 
LABAs in asthmatic patients with B16-Arg/Arg 
genotype for the use of LABAs have been relativ-
ized, this study demonstrated again the non-infe-
riority of tiotropium to salmeterol in moderate 
asthmatic patients and supports that tiotropium 
might be an alternative add-on to an ICS treat-
ment option in asthmatic patients.
The first long-term study with an active treat-
ment period of 48 weeks was performed with 
912 severely asthmatic patients, who had symp-
toms despite a high dose of ICS plus LABA 
[Kerstjens et al. 2012]. A dose of 5 μg tiotropium 
once daily or placebo was added to the mainte-
nance therapy. Peak FEV1 response occurred 
within three hours of the administration of the 
maintenance and the study drugs, and the trough 
FEV1 response, improved significantly from the 
baseline after 24 weeks in the tiotropium group, 
compared with the placebo group. Likewise, the 
time to the first severe asthma exacerbation 
increased (with a reduction of 21% in risk, and a 
hazard ratio of 0.79, p = 0.03). Further second-
ary endpoints (peak FVC and trough vital 
capacity; morning and evening PEF) improved 
significantly. The incidence of adverse events 
was comparable in both groups, with only higher 
rates of allergic rhinitis in the tiotropium group 
and higher rates of asthmatic episodes and 
insomnia in the placebo group. The patients 
that were included in this study were uncon-
trolled asthmatic patients despite high doses of 
an ICS plus LABA. Therapeutic alternatives are 
limited in these patients. Although the changes 
of the symptom and quality of life scores were 
low, this study demonstrates that an additional 
treatment with tiotropium significantly reduces 
the rate of asthma exacerbations and improves 
lung function in this difficult to treat patient 
group.
Several dose-finding and therapy regimen 
studies followed the long-term treatment study 
by Kerstjens and colleagues [Kerstjens et al. 
2012]. In a randomized, double-blind, placebo- 
controlled, four-way crossover study, 149 moder-
ately symptomatic asthmatic patients treated with 
stable medium-dose ICS without LABA were 
randomized to three different tiotropium dosages 
versus placebo (1.25, 2.5 or 5 µg, administered 
once daily in the evening) [Beeh et  al. 2014]. 
Each treatment was performed for a period of 4 
weeks. The primary endpoint peak FEV1 within 
the first 3 hours post-dose (0–3h) improved 
significantly in all three tiotropium dosage groups 
Therapeutic Advances in Respiratory Disease 10(6)
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(p < 0.0001), with the largest difference from the 
placebo group being with 5 μg. Furthermore, a 
dose-dependent increase was also observed for 
the trough FEV1, the FEV1 area under the curve 
(0–3h), the peak FVC (0–3h), the trough FVC 
and the FVC area under the curve (0–3h), with 
the largest increase with 5 μg. Although the treat-
ment periods of only 4 weeks were very short, a 
superiority of the highest tested dose concerning 
changes in lung function could be demonstrated, 
while the safety profile was comparable between 
the different doses and placebo.
A Japanese study with 285 symptomatic asth-
matic patients, who were treated with ICS and 
LABAs, compared the long-term safety and effect 
on lung function of two different doses of tiotro-
pium (2.5 and 5 μg), administered for 52 weeks, 
with a placebo [Ohta et al. 2015]. The adjusted 
mean trough FEV1 and the trough PEF were sig-
nificantly higher with tiotropium 5 μg compared 
with the placebo, but not with 2.5 μg. ACQ-7 
improved more in both tiotropium groups com-
pared with the placebo. The incidence of adverse 
events was similar in the tiotropium and the pla-
cebo groups; however, bronchitis was more fre-
quently reported in the tiotropium groups.
These results were supported by a randomized, 
double-blind, placebo-controlled crossover dose 
regimen study with 89 symptomatic asthmatic 
patients [Timmer et al. 2015]. Subjects received 
add-on treatment to medium-dose ICS with 5 μg 
tiotropium once daily, or 2.5 μg twice daily, com-
pared with placebo. There were no significant dif-
ferences between the 5 μg once daily and 2.5 μg 
twice daily groups in all investigated lung func-
tion parameters, but significant improvement 
compared with the placebo group with regard to 
the FEV1 area under the curve from 0 to 24 h 
response, the peak FEV1 (0–24h), the trough 
FEV1 and the pre-dose PEF (am/pm).
Pooled data of two randomized, placebo-con-
trolled, parallel-group studies with symptomatic 
asthmatic patients, who remained symptomatic 
despite the administration of a medium-dose 
ICS, confirmed the significant improvement of 
lung function during a 24 week treatment period 
[Kerstjens et  al. 2015]. Patients were either 
treated with 5 or 2.5 μg tiotropium once daily, or 
with salmeterol 50 μg twice daily, or with a pla-
cebo, in addition to their maintenance ICS. Both 
the peak and trough FEV1 responses and the 
ACQ-7 response were significantly greater in all 
actively-treated patients compared with the pla-
cebo patients, with no relevant differences 
between the tiotropium groups and the salmet-
erol group. The safety profile was similar in all 
four treatment groups.
When summarizing the results of the dose-finding 
studies, all tested tiotropium dosages showed 
superiority to placebo in most lung function 
parameters. The highest dose of 5 μg resulted in 
the most significant improvement of lung func-
tion in some studies, but this was not consistent. 
The safety profile, however, was comparable with 
placebo without relevant differences between the 
different doses.
Tiotropium add-on to ICS non-placebo 
controlled studies
Results from the BELT study recently confirmed 
the non-inferiority of tiotropium add-on to ICS, 
compared with salmeterol in moderate-to-severe, 
black asthmatic patients [Wechsler et  al. 2015]. 
No differences in the number of asthma episodes 
requiring an unscheduled visit, change of FEV1, 
symptom questionnaires, number of symptom-
free days or the need for rescue medication could 
be seen between the two different treatment 
regimens. Allelic variation at the Arg16Gly locus 
of the β2-adrenergic receptor (‘ADRB’) gene 
locus did not affect the results.
A single-centre Chinese study comparing the 
effect of add-on treatment with tiotropium 5 μg or 
LTRA and the effect of doubling the dose of ICS 
in uncontrolled asthmatic patients using inhaled 
salmeterol/fluticasone 50/250 μg demonstrated 
no significant difference between the tiotropium 
group and the ‘doubling of the dose of ICS’ group 
with regard to the PEF variability or the ACT 
score after 16 weeks of treatment [Wang et  al. 
2015]. Fractionated exhaled nitric oxide (FeNO) 
concentration was significantly higher in the tio-
tropium group compared with the double-dose 
ICS group, but the risk of pneumonia was lower.
A recently published, double-blind, two-way 
crossover study investigated the total tiotropium 
exposure, expressed as area under the plasma 
concentration versus time curve over 24 hours, in 
asthmatic patients, who were symptomatic 
despite receiving a medium dose of ICS [Beeh 
et al. 2016]. The study participants were either 
treated with tiotropium 5 μg once daily or 2.5 μg 
twice daily, as an add-on to their maintenance 
C Vogelberg
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therapy, for 4 weeks. The total tiotropium expo-
sure did not differ significantly between the two 
dosage groups, thus supporting 5 μg as a suitable 
dosage.
The limited number of studies that compared dif-
ferent treatment strategies demonstrated a non-
inferiority of an add-on treatment with tiotropium 
to ICS compared with a combination of salmet-
erol and ICS. These data might indicate the 
potential of tiotropium as a safe and effective ster-
oid-sparing treatment alternative. However, more 
studies, especially investigating the treatment 
effect on asthmatic inflammation are needed to 
assess the best treatment combination.
Real-life studies
Only a few studies investigating tiotropium in 
asthmatic patients under real-life conditions have 
been published so far. Abadoglu and Berk 
reported the effect of add-on treatment with tio-
tropium in severely asthmatic patients, compar-
ing the number of exacerbations, emergency 
department visits, hospitalizations and changes of 
lung function in the 12 months before and after 
the onset of the treatment [Abadoglu and Berk, 
2016]. All endpoints improved significantly; 
asthma control improved in 42.2%, the number 
of emergency department visits decreased in 
46.9%, and the number of hospitalizations 
decreased in 50% of the patients. The FEV1% 
and FVC % rates also improved significantly.
These results are supported by a recently pub-
lished real-life care study [Price et  al. 2015]. 
Records from the UK’s Optimum Patient Care 
Research Database from 2001–2013 revealed a 
significant decrease of asthma exacerbation and 
acute respiratory events in the 2042 study 
patients, leading to significantly reduced antibi-
otic prescription and oral corticosteroid courses. 
In this study, no significant changes of lung func-
tion were documented; however, the usage of 
short-acting β2-agonists increased significantly.
Although randomized, controlled trials are essen-
tial to evaluate the efficacy and limits of a new 
therapy, comparative observational studies are 
important to verify these data in a real-life setting. 
On this note, more observational studies are 
needed to better estimate the therapeutic poten-
tial of tiotropium in different patients and to bet-
ter understand which kind of asthma patients 
benefit more or less from tiotropium.
Conclusion
Only recently has tiotropium been included as the 
first long-acting anticholinergic agent in the GINA 
guidelines. Compared with other long-acting 
anticholinergic substances, there is substantial 
clinical evidence for the therapeutic benefit of an 
add-on therapy with tiotropium in adult patients 
with insufficiently controlled asthma. Most of the 
studies in adults included patients aged 18–75, but 
there is also a rising body of paediatric studies with 
similar results [Vogelberg et  al. 2014, 2015; 
Hamelmann et al. 2016]. Thus, tiotropium might 
extend treatment options both in children starting 
at age of 6 years and adults. Both the relevant lung 
function parameters and the indicators for asthma 
control improve with add-on treatment with tio-
tropium. The first preliminary studies also demon-
strate non-inferiority compared with the add-on 
treatment with salmeterol, and all studies report an 
excellent safety profile of the drug. The pharmaco-
logical properties of tiotropium suggest that rele-
vant effects in asthma therapy include not only 
bronchodilation but also anti-inflammatory 
impact. This again might explain the changes of 
lung function but also the increase of time until the 
first exacerbation and the reduction of severe exac-
erbation [Kerstjens et al. 2012]. Although tiotro-
pium is presently recommended as an alternative 
add-on treatment option in steps 4 and 5, further 
studies will be needed to finally evaluate the poten-
tial of the drug with respect to asthma treatment. 
This also includes the need for additional head-to-
head studies to define the position that tiotropium 
ought to have in asthma guidelines. Further real-
life studies might help to identify asthmatic patients 
who would benefit most from tiotropium.
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